Oruka Therapeutics, Inc. (ORKA)

Order flow on ORKA suggests systematic accumulation by long-only institutional accounts during yesterday's dip.

Secondary debt liquidity for ORKA proxies remains highly resilient despite headline noise. Watching gross margin expansion.

On our desk, ORKA has been an absolute standout in the healthcare space. With all 8 covering Wall Street analysts issuing firm buy ratings and consensus targets pointing well above current trading levels around $113, the institutional sentiment is undeniably bullish. We are closely tracking how traders maintain clean intraday ranges off the low-$80s support base, though we remain mindful that a valuation near a $6.82 billion market cap demands continuous execution on their clinical milestones to sustain this kind of premium.

In our clinic and research evaluations, the focus is squarely on the therapeutic differentiation of ORKA-001 and ORKA-002 for plaque psoriasis and psoriatic arthritis. Watching the progression across trials like EVERLAST-A, EVERLAST-B, ORCA-SURGE, and ORCA-SPLASH gives us critical insight into their pharmacokinetic profile and potential dosing advantages. Management's stated runway to fund operations through the anticipated BLA filing for ORKA-001 provides a clear operational timeline that clinical investigators and biotech portfolios must monitor closely.